Dupilumabe e linfoma cutâneo de células T: vigilância diagnóstica, terapêutica segura
Dupilumab and cutaneous T-cell lymphoma: diagnostic surveillance, safe therapy
Sérgio Duarte Dortas Junior, Marcelo Vivolo Aun, Aldo José Fernandes Costa, Fabrício Prado Monteiro, Filipe Wanick Sarinho, Marta de Fátima Rodrigues da Cunha Guidacci, Martti Antila, João Negreiros Tebyriça, Nelson Augusto Rosário Filho, Norma de Paula Motta Rubini
Referências
1. Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139-47. https://doi.org/10.1016/j.jaad.2020.08.051. PMid:32822798.
2. Larney C, Foley P, Wu J, Daniel BS. Real world side-effects of dupilumab: a narrative review. Australas J Dermatol. 2025;66(6): e324-34. https://doi.org/10.1111/ajd.14557. PMid:40557973.
3. Amatore F, Neildez M, de Masson A, Battistella M, Tauber M, Ingen-Housz-Oro S et al. Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus. J Eur Acad Dermatol Venereol. 2026;40(8):1344-58. https://doi.org/10.1111/jdv.70407. PMid:41821352.
4. Hasan I, Parsons L, Duran S, Zinn Z. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. J Am Acad Dermatol. 2024;91(2):255-8. https://doi.org/10.1016/j.jaad.2024.03.039. PMid:38588818.
5. Calvão J, de Masson A, Cozzio A, Assaf C, Jonak C, Hodak E et al. Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group. J Allergy Clin Immunol. 2026;157(6): 1237-45. https://doi.org/10.1016/j.jaci.2026.04.002. PMid:41967816.
6. Costa AJF, Aun MV, Dortas-Junior SD, Monteiro FP, Sarinho FW, Guidacci MFRC et al. Eventos adversos associados ao dupilumabe no tratamento de doenças inflamatórias crônicas tipo 2. Arq Asma Alerg Imunol. 2025;9(4):400-7.
Submetido em:
03/07/2026
Aceito em:
19/08/2026
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email